---
layout: default
title: Sulfamethazine
description: "Sulfamethazine 的老藥新用潛力分析。模型預測等級 L5，包含 6 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 僅模型預測 (L5)
nav_order: 161
evidence_level: L2
indication_count: 6
---

# Sulfamethazine

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L5</strong> | 預測適應症: <strong>6</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Sulfamethazine（磺胺二甲嘧啶）：從抗菌劑到多元感染症之探索

## 一句話總結

<p class="key-answer" data-question="Sulfamethazine 可以用於治療什麼新適應症？">
Sulfamethazine 是傳統磺胺類廣效抗菌劑，TxGNN 預測其可能對糖尿病腎病變及結膜炎有潛力，有文獻支持其與糖尿病微血管病變的藥物代謝關聯，但台灣所有許可證均已註銷。
</p>


## 快速總覽

| 項目 | 內容 |
|------|------|
| 原適應症 | 磺胺劑、革蘭氏陽性及陰性菌感染症 |
| 預測新適應症 | gout、brain small vessel disease 1 with or without ocular anomalies、autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome、diabetic nephropathy、conjunctivitis、bronchitis |
| TxGNN 預測分數 | 0.998（diabetic nephropathy） |
| 證據等級 | L4（有 PubMed 文獻支持） |
| 台灣上市 | 所有許可證已註銷 |
| 許可證數 | 59 張（全部已註銷） |
| 建議決策 | Hold |




## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. gout</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.87%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p><p class="key-answer" data-question="這個藥物的作用機轉是什麼？"></p>

<h3>臨床試驗</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01245127" target="_blank">NCT01245127</a></td><td>PHASE2</td><td>COMPLETED</td><td>1</td><td>Ilaris (Canakinumab) in the Schnitzler Syndrome. A Case Series.</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06695182" target="_blank">NCT06695182</a></td><td>N/A</td><td>ACTIVE_NOT_RECRUITING</td><td>3000</td><td>the Real-world Data of Risk Factor and Its Prognosis in PREmature Coronary ARter...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. brain small vessel disease 1 with or without ocular anomalies</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（19 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35882526/" target="_blank">35882526</a></td><td>2023</td><td>Article</td><td>Journal of medical g</td><td>Axenfeld-Rieger syndrome: more than meets the eye.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30182440/" target="_blank">30182440</a></td><td>2018</td><td>Article</td><td>American journal of </td><td>Neuropathology of holoprosencephaly.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33870948/" target="_blank">33870948</a></td><td>2022</td><td>Article</td><td>Journal of neuro-oph</td><td>Optic Nerve Aplasia.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11941259/" target="_blank">11941259</a></td><td>2002</td><td>Article</td><td>Journal francais d&#x27;o</td><td>[Congenital megalocornea].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6390155/" target="_blank">6390155</a></td><td>1983</td><td>Article</td><td>Neurologic clinics</td><td>Optic disk abnormalities.</td></tr>
</tbody>
</table>
<p><em>...及其他 14 篇文獻</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. diabetic nephropathy</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.77%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（3 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06843304" target="_blank">NCT06843304</a></td><td>N/A</td><td>RECRUITING</td><td>2000</td><td>The Intelligent Prevention And Control System And Strategy For The Whole Disease...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06254677" target="_blank">NCT06254677</a></td><td>N/A</td><td>NOT_YET_RECRUITING</td><td>1000</td><td>Western Sydney Kidney Injury Biopsy Study</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03191396" target="_blank">NCT03191396</a></td><td>PHASE3</td><td>COMPLETED</td><td>577</td><td>Efficacy and Safety of Semaglutide 1.0 mg Once-weekly Versus Liraglutide 1.2 mg ...</td></tr>
</tbody>
</table>

<h3>相關文獻（1 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9112055/" target="_blank">9112055</a></td><td>1997</td><td>Article</td><td>European journal of </td><td>N-acetylation and hydroxylation polymorphisms in type II dia...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. conjunctivitis</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.43%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（4 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/1258314/" target="_blank">1258314</a></td><td>1976</td><td>Article</td><td>The Veterinary recor</td><td>Infectious bovine keratoconjunctivitus.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27893834/" target="_blank">27893834</a></td><td>2016</td><td>Article</td><td>PloS one</td><td>Selective Pressure Promotes Tetracycline Resistance of Chlam...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4563744/" target="_blank">4563744</a></td><td>1972</td><td>Article</td><td>Revue internationale</td><td>[The evaluation of controlled trachoma chimiotherapy trial].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4852056/" target="_blank">4852056</a></td><td>1974</td><td>Article</td><td>Archives of ophthalm</td><td>Five-year perspective on trachoma in the San Xavier Papago I...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. bronchitis</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.34%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（5 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03964766" target="_blank">NCT03964766</a></td><td>NA</td><td>UNKNOWN</td><td>42</td><td>Postoperative Pain Following Pulpectomy of Primary Molars With Rotary Instrument...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02742597" target="_blank">NCT02742597</a></td><td>NA</td><td>COMPLETED</td><td>175</td><td>Patient-Centred Innovations for Persons With Multimorbidity - Ontario</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03378661" target="_blank">NCT03378661</a></td><td>PHASE2</td><td>UNKNOWN</td><td>210</td><td>Phase 2 Randomized, Multicenter, Safety and Efficacy Trial to Evaluate Different...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01251003" target="_blank">NCT01251003</a></td><td>PHASE1, PHASE2</td><td>WITHDRAWN</td><td>0</td><td>Safety of Autologous Human Umbilical Cord Blood Treatment for Traumatic Brain in...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02789800" target="_blank">NCT02789800</a></td><td>NA</td><td>COMPLETED</td><td>284</td><td>Patient-Centred Innovations for Persons With Multimorbidity - Quebec</td></tr>
</tbody>
</table>

<h3>相關文獻（3 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/46968/" target="_blank">46968</a></td><td>1975</td><td>Article</td><td>Lancet (London, Engl</td><td>Editorial: Antimicrobial treatment of chronic bronchitis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2849814/" target="_blank">2849814</a></td><td>1988</td><td>Article</td><td>Thorax</td><td>Clinical experience in the management of pulmonary opportuni...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/1884803/" target="_blank">1884803</a></td><td>1991</td><td>Article</td><td>Farmakologiia i toks</td><td>[The pharmacokinetics of the marker preparations antipyrine ...</td></tr>
</tbody>
</table>

</div>
</details>


## 台灣上市資訊

| 許可證號 | 品名 | 劑型 | 核准適應症 | 狀態 |
|---------|------|------|-----------|------|
| 衛署藥輸字第000257號 | 磺胺二甲嘧啶 | （粉） | 革蘭氏陽性菌及陰性菌感染症 | 已註銷 |
| 內衛藥製字第005289號 | 命多磺淨粉 | 散劑 | 細菌感染症 | 已註銷 |
| 內衛藥製字第001516號 | 命多磺淨錠 | 錠劑 | 細菌感染症 | 已註銷 |
| 衛署藥製字第019713號 | 泄卜菌錠 | 錠劑 | 呼吸道、胃腸道、尿道感染症 | 已註銷 |
| 內衛藥輸字第003821號 | 沙發美星粉 | （粉） | 細菌性感染症 | 已註銷 |

**注意：所有 Sulfamethazine 相關許可證均已註銷。**

## 安全性考量

- **警語與禁忌症**：
  - 磺胺類藥物過敏者禁用
  - Stevens-Johnson 症候群及中毒性表皮壞死症風險
  - 血液疾病風險（顆粒球缺乏症、再生不良性貧血）

- **藥物交互作用**：
  - 增強 Warfarin 抗凝血作用
  - 增強 Methotrexate 毒性
  - 與 Trimethoprim 合用可增強抗菌效果（複方使用）

- **特殊族群**：
  - G6PD 缺乏症患者需謹慎
  - 妊娠末期及新生兒禁用（核黃疸風險）
  - 腎功能不全需調整劑量

## 結論與下一步

**決策：Hold**

**理由：**
1. 台灣所有許可證均已註銷，需重新申請上市許可
2. 糖尿病腎病變預測雖有藥物代謝文獻支持，但 Sulfamethazine 在該研究中僅作為探針藥物，非治療用途
3. 結膜炎及支氣管炎等感染症已有更安全有效的現代抗生素
4. 磺胺類藥物的安全性問題（過敏、血液毒性）限制其臨床應用

**若要推進需要：**
- 重新申請藥品許可證
- 與現代抗生素的頭對頭比較研究
- 針對特定抗藥性菌株的評估
- 成本效益分析

**建議：**
除非針對特定抗藥性問題或資源有限地區的需求，否則不建議投入資源重新開發此藥物。糖尿病腎病變的預測更適合作為藥物代謝研究參考，而非直接治療應用。


---

## 相關藥物報告

- [Potassium Iodide]({{ "/drugs/potassium_iodide/" | relative_url }}) - 證據等級 L5
- [Famotidine]({{ "/drugs/famotidine/" | relative_url }}) - 證據等級 L5
- [Paclitaxel]({{ "/drugs/paclitaxel/" | relative_url }}) - 證據等級 L5
- [Warfarin]({{ "/drugs/warfarin/" | relative_url }}) - 證據等級 L5
- [Aluminum Chloride]({{ "/drugs/aluminum_chloride/" | relative_url }}) - 證據等級 L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Sulfamethazine老藥新用驗證報告. https://twtxgnn.yao.care/drugs/sulfamethazine/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_sulfamethazine,
  title = {Sulfamethazine老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/sulfamethazine/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
